Evercore ISI Group Initiates Coverage On Biomarin Pharmaceutical with Outperform Rating, Announces Price Target of $113
Portfolio Pulse from Benzinga Newsdesk
Evercore ISI Group has initiated coverage on Biomarin Pharmaceutical (BMRN) with an Outperform rating and a price target of $113.
May 14, 2024 | 9:11 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Evercore ISI Group's initiation of coverage on Biomarin Pharmaceutical with an Outperform rating and a price target of $113 is a positive development for the company, indicating a bullish outlook from the analyst.
Analyst ratings and price targets can significantly influence investor perception and stock price. An Outperform rating combined with a high price target suggests that Evercore ISI Group sees strong growth potential or undervaluation in BMRN, which could lead to increased investor interest and a potential rise in stock price in the short term.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100